Gilead sales and marketing update

Gilead disclosed European pricing for newly launched HCV drug Sovaldi sofosbuvir on a conference call to discuss its 4Q13 and 2013 financial results. Gilead said that a 12-week course of the drug is priced at almost £35,000 ($57,382) in the U.K. and at almost €49,000 ($66,135) in Germany. In the U.S., the wholesale acquisition cost of a 12-week course of Sovaldi is $84,000. The European Commission approved Sovaldi in January in combination with ribavirin for 24 weeks as an all-oral therapy to treat HCV genotypes 2 and 3 infection. The EC also approved Sovaldi in combination with ribavirin and pegylated interferon to treat HCV genotypes 1, 4, 5 and 6 infections; the all-oral regimen is indicated for these patients when they are ineligible or intolerant to peginterferon. The approval also covers use of Sovaldi in combination with ribavirin for patients with HCV who are awaiting liver transplantation. ...